RADIANCE – Radiochemotherapy with or without Durvalumab in the treatment of anal squamous cell carcinoma: A randomized multicenter phase II trial

RADIANCE – Radiochemotherapy with or without Durvalumab in the treatment of anal squamous cell carcinoma: A randomized multicenter phase II trial

Purpose: Anal squamous cell carcinomas (ASCC) are increasing in frequency across the developed world. The 3-year disease-free survival (DFS) in patients with locally-advanced disease is approximately 60% after primary radiochemotherapy (RCT). There is a strong rationale for combining immunotherapy w...

Full description

Bibliographic Details
Main Authors: Daniel Martin, Panagiotis Balermpas, Johannes Gollrad, Christian Weiß, Chiara Valentini, Martin Stuschke, Henning Schäfer, Christoph Henkenberens, Jürgen Debus, David Krug, Thomas Kuhnt, Thomas Brunner, Tilman Bostel, Rita Engenhart-Cabillic, Ursula Nestle, Stephanie E. Combs, Claus Belka, Matthias Hautmann, Guido Hildebrandt, Cihan Gani, Bülent Polat, Claus Rödel, Emmanouil Fokas
Format: Article
Language:English
Published: Elsevier 2020-07-01
Series:Clinical and Translational Radiation Oncology
Subjects:
Anal cancer
Durvalumab
Immunotherapy
Radiochemotherapy
Phase 2
Disease-free survival
Online Access:http://www.sciencedirect.com/science/article/pii/S2405630820300343

Internet

http://www.sciencedirect.com/science/article/pii/S2405630820300343

Similar Items